Minutoli F, Di Bella G, Mazzeo A, Laudicella R, Gentile L, Russo M, Vita G, Baldari S
Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, University Hospital "G. Martino", Via Consolare Valeria 1, 98125, Messina, Italy.
Department of Clinical and Experimental Medicine, University of Messina, University Hospital "G. Martino", Via Consolare Valeria 1, 98125, Messina, Italy.
J Nucl Cardiol. 2021 Oct;28(5):1949-1957. doi: 10.1007/s12350-019-01950-2. Epub 2019 Nov 18.
To determine the capability of Tc-DPD scintigraphy to detect early cardiac involvement and predict clinical worsening in transthyretin (TTR) gene mutation patients.
Eleven mutated subjects with normal interventricular septum (IVS) thickness, NT-proBNP level and no cardiac symptoms underwent three seriate Tc-DPD scans (visually and semiquantitatively analyzed), and was followed-up for 5-8-years.
Six patients showed no myocardial accumulation in all scans. Increased IVS thickness occurring in one patient 4 years after the last scan was the only abnormal finding in these patients; no cardiac symptoms developed during the follow-up. In three patients, cardiac radiotracer uptake was found at enrollment; other laboratory/instrumental abnormal findings occurred later and cardiac symptoms developed during the follow-up period. Two patients had a negative Tc-DPD scan at enrollment and showed cardiac uptake in the following scans. Increased mean left-ventricular (LV) wall thickness was found 3 years after positive scintigraphy; NT-proBNP increased later in one patient. These patients developed cardiac symptoms during the follow-up period.
Tc-DPD scan detects cardiac involvement in subjects with TTR gene mutation earlier than ECG, echocardiography and biochemical markers, occurring some years before the fulfillment of current diagnostic criteria for cardiac amyloidosis. A positive Tc-DPD scan predicts cardiac symptoms onset.
确定锝-二膦酸盐闪烁扫描术检测转甲状腺素蛋白(TTR)基因突变患者早期心脏受累情况及预测临床病情恶化的能力。
11名室间隔(IVS)厚度正常、N末端脑钠肽前体(NT-proBNP)水平正常且无心脏症状的突变受试者接受了3次连续的锝-二膦酸盐扫描(进行视觉和半定量分析),并随访5至8年。
6名患者在所有扫描中均未显示心肌摄取增加。1名患者在最后一次扫描4年后出现室间隔厚度增加,这是这些患者唯一的异常发现;随访期间未出现心脏症状。3名患者在入组时发现心脏放射性示踪剂摄取增加;其他实验室/仪器检查异常发现较晚出现,且随访期间出现心脏症状。2名患者入组时锝-二膦酸盐扫描结果为阴性,随后的扫描显示心脏摄取增加。阳性闪烁扫描3年后发现平均左心室(LV)壁厚度增加;1名患者的NT-proBNP随后升高。这些患者在随访期间出现了心脏症状。
锝-二膦酸盐扫描比心电图、超声心动图和生化标志物更早检测到TTR基因突变患者的心脏受累情况,在达到目前心脏淀粉样变性诊断标准的数年前就会出现。阳性锝-二膦酸盐扫描可预测心脏症状的出现。